RT Journal Article
SR Electronic
T1 Microfluidic Affinity Profiling reveals a Broad Range of Target Affinities for Anti-SARS-CoV-2 Antibodies in Plasma of COVID-19 Survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.20.20196907
DO 10.1101/2020.09.20.20196907
A1 Schneider, Matthias M.
A1 Emmenegger, Marc
A1 Xu, Catherine K.
A1 Morales, Itzel Condado
A1 Meisl, Georg
A1 Turelli, Priscilla
A1 Zografou, Chryssa
A1 Zimmermann, Manuela R.
A1 Frey, Beat M.
A1 Fiedler, Sebastian
A1 Denninger, Viola
A1 Jacquat, Raphaël P. B.
A1 Madrigal, Lidia
A1 Ilsley, Alison
A1 Kosmoliaptsis, Vasilis
A1 Fiegler, Heike
A1 Trono, Didier
A1 Knowles, Tuomas P. J.
A1 Aguzzi, Adriano
YR 2021
UL http://medrxiv.org/content/early/2021/09/08/2020.09.20.20196907.abstract
AB The clinical outcome of SARS-CoV-2 infections, which can range from asymptomatic to lethal, is crucially shaped by the concentration of antiviral antibodies and by their affinity to their targets. However, the affinity of polyclonal antibody responses in plasma is difficult to measure. Here we used Microfluidic Antibody Affinity Profiling (MAAP) to determine the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 19 of which were healthy donors, 20 displayed mild symptoms, and 3 were critically ill. We found that dissociation constants, Kd, of anti-receptor binding domain antibodies spanned 2.5 orders of magnitude from sub-nanomolar to 43 nM. Using MAAP we found that antibodies of seropositive individuals induced the dissociation of pre-formed spike-ACE2 receptor complexes, which indicates that MAAP can be adapted as a complementary receptor competition assay. By comparison with cytopathic-effect based neutralisation assays, we show that MAAP can reliably predict the cellular neutralisation ability of sera, which may be an important consideration when selecting the most effective samples for therapeutic plasmapheresis and tracking the success of vaccinations.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. VD, SF, HF are employees of Fluidic Analytics, MMS, CKX, GM and VK are consultants. All other authors declare no competing interests.Funding StatementWe acknowledge financial support from the BBRSC to TPJK, as well as the Frances and Augustus Newman Foundation to TPJK; the ERC PhyProt (agreement no. 337969) to MMS, CKX, MRZ, GM and TPJK; the Centre for Misfolding Diseases, Cambridge to MMS, CKX, GM, and TPJK; St John's College Cambridge to MMS, MRZ and TPJK; as well as CKX and MRZ from the Herchel Smith Fund; ICM acknowledges funding from the Swiss FCS and the Forschungskredit of the University of Zurich. Institutional core funding by the University of Zurich and the University Hospital of Zurich, as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Network to AA; Funding by grants of Innovation Fund of the University Hospital Zurich to AA and ME. VK acknowledges funding from NIHR (PDF-2016-09-065).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments and analyses involving samples from human donors were conducted with the approval of the local ethics committee of the Canton Zurich (Kantonale Ethikkommission Kanton Zurich). The study is covered by the following applications to above-mentioned local ethics committee: KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731. We obtained approval for all applications. The experiments and analyses were carried out in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make efforts to provide microliter amounts of samples to other researchers, their availability is physically limited.